Microbot Medical Inc.

NASDAQ:MBOT

Medical - Instruments & Supplies

Healthcare
$0.98 -2.93%

-$0.06 today

Market cap
$65.73M
Beta
1.04
P/E (TTM)
-8.6
EPS (TTM)
-$0.21
52W Low $1.60High $4.67

Volume 0.87M

Average 1.60M

MBOT Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Microbot Medical Inc.NASDAQ: MBOT

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses growth accelerates

Q1 FY2026 operating expenses of $4.32M rose 43.1% year over year, ahead of the +31.0% change in trailing-twelve-month operating expenses. Sequentially, it rose 4.4% from the prior quarter. Over 3 fiscal years it compounded at +3.5% a year.

Context

  • Operating expenses increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +43.1% holds above the trailing-twelve-month pace of +31.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.32M+4.4% QoQ
Last fiscal yearDec 2025
$14.74M+27.8% YoY
LTMMar 2026
$16.03M+31.0% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+43.1%——
1 year+27.8%——
3-year CAGR+3.5%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
14.74M USD
Year-over-year change
+27.8%
4-year CAGR
+6.7%

Operating Expenses vs competitors

How MBOT compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +31.0% is the 2nd highest of 10, against a peer median of -0.8%.
  • Operating expenses amounts to 15268.6% of revenue for MBOT, versus a peer median of 769.8%.
MBOT Competitors
Operating Expenses for MBOT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DCGODocGo Inc.LTM Mar 2026$199.76M USD+12.0%+12.2%66.2%
RCELAVITA Medical, Inc.LTM Mar 2026$98.38M USD-12.5%+21.7%136.0%
OVIDOvid Therapeutics Inc.LTM Mar 2026$54.82M USD-4.8%-4.7%769.8%
CNTXContext Therapeutics Inc.LTM Mar 2026$43.51M USD+37.6%+37.2%—
CRDLCardiol Therapeutics Inc.LTM Mar 2026CA$35.59M CAD+1.4%+4.2%—
VANIVivani Medical, Inc.LTM Mar 2026$27.68M USD+11.1%+8.5%—
CLNNClene Inc.LTM Mar 2026$20.57M USD-27.1%-21.9%15353.0%
MBOTMicrobot Medical Inc.LTM Mar 2026$16.03M USD+31.0%+3.5%15268.6%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$14.22M USD-0.8%-29.6%—
ZTEKZentek Ltd.LTM Mar 2026CA$6.32M CAD-15.4%-31.0%3803.5%
Peer median (excluding MBOT) —-0.8%+4.2%769.8%

Competitors are the stored peer set for MBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00106K91K0
Gross Profit00(106K)(91K)0
Gross Margin—————
Research & Development6.15M7.74M5.72M6.63M6.28M
Selling, General & Admin5.41M5.58M4.13M5M8.25M
Operating Expenses11.36M13.28M9.75M11.53M14.74M
Depreciation & Amortization76K102K106K91K47K
EBITDA(11.24M)(13.34M)(10.63M)(11.35M)(13.1M)
EBITDA Margin—————
Operating Income(11.36M)(13.28M)(9.86M)(11.63M)(14.74M)
Operating Margin—————
Interest Income44K54K228K182K1.29M
Interest Expense00000
Other Income / Expenses44K113K(885K)182K1.6M
Income Before Tax(11.31M)(13.17M)(10.74M)(11.44M)(13.14M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(11.31M)(13.17M)(10.74M)(11.44M)(13.14M)
Net Margin—————
EPS (Basic)(1.59)(1.81)(1.05)(0.73)(0.29)
EPS (Diluted)(1.59)(1.81)(1.05)(0.73)(0.29)
Weighted Avg Shares7.11M7.26M10.2M15.65M45.79M
Weighted Avg Shares (Diluted)7.11M7.26M10.2M15.65M45.79M

Microbot Medical Inc.

NASDAQ:MBOT

Intrinsic Alpha fair value

Locked

Current Price

$0.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.